MedTrace Logo

Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections

NCT02951351 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2023-04-12

Study results available
· View outcomes & findings →

Summary

The specific aims of this study are to compare patient experience with and without a proparacaine drop after povidone iodine.

Conditions

  • Age-related Macular Degeneration
  • Diabetic Macular Edema
  • Injection Site
  • Injection Site Infection
  • Pain, Postoperative

Interventions

DRUG

Proparacaine

Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.

PROCEDURE

Conjunctival culture

Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.

Sponsors & Collaborators

  • VitreoRetinal Surgery, PA

    collaborator OTHER

  • Research to Prevent Blindness

    collaborator OTHER

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Jose S Pulido, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-12
Primary Completion
2018-02-01
Completion
2018-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02951351 on ClinicalTrials.gov